Blood-based Biomarkers of Alzheimer's Disease: The Long and Winding Road

Autor(es)

Manzine, Patricia R. ^[1] ; Vatanabe, Izabela P. ^[1] ; Peron, Rafaela ^[1] ; Grigoli, Marina M. ^[1] ; Pedroso, V, Renata ; Nascimento, Carla M. C. ^[2] ; Cominetti, Marcia R. ^[2]

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Carlos, Dept Gerontol, Rod Washington Luis, Km 235, Sao Carlos 13565905, SP - Brazil

^[2] Pedroso, Renata, V, Univ Fed Sao Carlos, Dept Gerontol, Rod Washington Luis, Km 235, Sao Carlos 13565905, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: CURRENT PHARMACEUTICAL DESIGN; v. 26, n. 12, p. 1300-1315, 2020.
• Citações Web of Science: 1

Resumo

Background: Blood-based biomarkers can be very useful in formulating new diagnostic and treatment proposals in the field of dementia, especially in Alzheimers disease (AD). However, due to the influence of several factors on the reproducibility and reliability of these markers, their clinical use is still very uncertain. Thus, up-to-date knowledge about the main blood biomarkers that are currently being studied is extremely important in order to discover clinically useful and applicable tools, which could also be used as novel pharmacological strategies for the AD treatment. Methods: A narrative review was performed based on the current candidates of blood-based biomarkers for AD to show the main results from different studies, focusing on their clinical applicability and association with AD pathogenesis. Objective: The aim of this paper was to carry out a literature review on the major blood-based biomarkers for AD, connecting them with the pathophysiology of the disease. Results: Recent advances in the search of blood-based AD biomarkers were summarized in this review. The biomarkers were classified according to the topics related to the main hallmarks of the disease such as inflammation, amyloid, and tau deposition, synaptic degeneration and oxidative stress. Moreover, molecules involved in the regulation of proteins related to these hallmarks were described, such as non-coding RNAs, neurotrophins, growth factors and metabolites. Cells or cellular components with the potential to be considered as blood-based AD biomarkers were described in a separate topic. Conclusion: A series of limitations undermine new discoveries on blood-based AD biomarkers. The lack of reproducibility of findings due to the small size and heterogeneity of the study population, different analytical methods and other assay conditions make longitudinal studies necessary in this field to validate these structures, especially when considering a clinical evaluation that includes a broad panel of these potential and promising blood-based biomarkers. (AU)

• Processo FAPESP: 16/06226-9 - ADAM10 como biomarcador de fragilidade cognitiva
• Beneficiário: Izabela Pereira Vatanabe
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 15/26084-1 - Avaliação da ADAM10 plaquetária em demências não-Alzheimer
• Beneficiário: Patricia Regina Manzine Moralles
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 19/02648-4 - Papel de proteínas da via de sinalização da insulina e sua relação com a secretase ADAM10 na Doença de Alzheimer
• Beneficiário: Márcia Regina Cominetti
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 17/18808-5 - Influência do genótipo da apolipoproteína E (APOE) e de fatores neurotróficos nos potenciais evocados (ERP-P300) de idosos com Doença de Alzheimer e idosos saudáveis
• Beneficiário: Renata Valle Pedroso
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 18/05446-0 - Níveis da ADAM10 inativa no plasma de indivíduos com comprometimento cognitivo leve e Doença de Alzheimer
• Beneficiário: Marina Mantellatto Grigoli
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica